Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
28.94-0.33 (-1.14%)
As of 1:08 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close29.27
Bid0.00 x
Ask0.00 x
Day's Range28.91 - 29.04
52wk Range28.91 - 35.13
1y Target EstN/A
Market Cap202.24B
P/E Ratio (ttm)21.73
Avg Vol (3m)994,285
Dividend & Yield1.02 (3.48%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Market Realist1 hour ago

    Roche’s Disappointing 3Q16 Earnings

    Roche Holding (RHHBY) reported earnings for 3Q16 on October 20, 2016. Wall Street analysts expected Roche to report 12.6 billion Swiss francs in revenue during 3Q16 while the company reported ~12.5 billion ...

  • Market Realist2 hours ago

    Biosimilars May Pose a Threat to Roche’s Herceptin

    Roche's Herceptin fetched nearly $6.6 billion during 2015, accounting for a 10% rise in annual sales.

  • PR Newswire6 hours ago

    LabCorp is first US laboratory to offer molecular testing with new fully automated cobas 8800 system from Roche

    OTCQX: RHHBY) and Laboratory Corporation of America® Holdings (LabCorp®) (LH) announced today that the LabCorp Center for Esoteric Testing in Burlington, N.C., is the first site in the United States to offer commercial testing services with Roche's new cobas® 8800 system. The system automates the entire molecular diagnostics testing process—from specimen preparation and nucleic acid extraction/purification through polymerase chain reaction (PCR) amplification and detection—and is the first high-throughput molecular system to be approved by the FDA for CLIA moderately complex testing. LabCorp, the world's leading healthcare diagnostics company, is initially running hepatitis C viral load testing on the system and plans to add testing for HIV and hepatitis B virus in the coming months.